Layoffs: Medical device companies cut 2,000 jobs in 2 months
September 14, 2012 by MassDevice staff
Cost-cutting moves by medical device companies have resulted in the loss of more than 2,000 jobs over the past 2 months.
Medical device companies are molting at a reptilian rate, shedding more than 2,000 jobs over the past 2 months as they look to slash costs across the board.
Several of the med-tech companies that are scrapping jobs say the 2.3% medical device excise tax in the Patient Protection and Affordable Care Act, slated to begin in January 2013. Others deny that the tax is the sole cause of their moves, saying it's a factor but not determinative.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Mobilizing on the back end of a disaster
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
Navigation
NEWS
Medical device tax: Consultant calls offshoring concerns 'horse hockey'
Concerns that the medical device tax will push companies to lay off workers and move operations...
FDA clears OrthoSensor's Verasense knee replacement device
The FDA clears OrthoSensor's Verasense device, designed to help surgeons fit knee replacement...
ArtVentive Medical wins CE Mark for peripheral catheter
ArtVentive Medical Group wins CE Mark approval in the European Union for its EOS peripheral vascular...
Recalls: FDA makes Endologix catheter introducer recall Class I
The FDA hits Endologix's catheter introducer device recall with Class I status, its most serious...
pSivida gains big on buyout rumor
A blogger's speculation that pSivida might be in line for a buyout bid sends the ophthalmology...
